VIVA! Communications marked the 18th annual PRIME Awards in style last night (Thursday, November 10, 2022) together with our much-valued clientele, Edwards Lifesciences and Dr Falk Pharma,  and Australian representatives from the pharmaceutical industry, at the Sofitel Wentworth Sydney Hotel.   Hosted by comedian, musician and former member of ABC TV’s satirical program, The Chaser,…

Read More

Australians living with types of aggressive stomach or oesophageal cancers can now access immunotherapy on the Pharmaceutical Benefits Scheme (PBS), representing the first treatment advance for many of these patients in a decade. OPDIVO® (nivolumab) in combination with chemotherapy, is now reimbursed as an initial treatment for patients with a type of stomach or oesophageal…

Read More

Tragically, every eight hours, one woman dies from ovarian cancer in Australia, equating to 1,042 women each year.1 Further estimates suggest that 1,720 women are diagnosed with ovarian cancer per annum, making it the eighth most common cancer in Australia.2 This month (February) is Ovarian Cancer Awareness Month – an important milestone on the public…

Read More

New Government data released today reveals disproportionate COVID-19 mortality and prevalence rates recorded among Australia’s culturally and linguistically diverse populations (CALD). The Australian Bureau of Statistics (ABS) data shows our nation has witnessed almost three times as many deaths from COVID-19 among those born overseas compared with those born locally (in Australia). The ABS data…

Read More

One in 10 Australians aged 65 years and above are living with dementia, the risk of diagnosis for which doubles every five years from aged 60. Dementia is not a specific disease, but rather, a broad term used to describe a group of symptoms that cause progressive damage to the brain. These symptoms include a…

Read More